NCT00551473View on ClinicalTrials.gov

Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2007

Conditions
Gastroesophageal Reflux DiseaseReflux, Gastroesophageal
Interventions
DRUG

Lavoltidine

Trial Locations (1)

2031

GSK Investigational Site, Randwick, Sydney

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY